Study of autophagy maintenance for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether a combination of medications (hydroxychloroquine, everolimus, and others) can help keep ovarian cancer from coming back after successful platinum chemotherapy plus Avastin. It is for people whose cancer responded well to their most recent chemo and who can continue Avastin maintenance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of ovarian, fallopian tube, or primary peritoneal cancer that came back at least 6 months after last platinum chemotherapy.
- You had at least 3 doses of bevacizumab (Avastin) with your chemo and plan to keep using it after treatment.
- Your current platinum chemo worked (partially or completely).
- You are 18 or older, have good kidney and liver function, and adequate blood counts.
- You are willing to stop taking certain medications (like statins) for a short time while on this study.
- You do not have a heart condition, uncontrolled diabetes, or other serious health issues that would make this trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding trastuzumab to standard maintenance therapy with bevacizumab for patients with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the combination helps keep the cancer from growing longer.
This trial tests whether a maintenance treatment with fluzoparib (a PARP inhibitor) plus bevacizumab can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation and whose cancer responded to initial chemotherapy.
This study compares two PARP inhibitors (drugs that help repair DNA damage) combined with bevacizumab (an anti-angiogenic therapy) as maintenance treatment after chemotherapy in patients with advanced ovarian cancer that has a genetic vulnerability called HRD-positive. The goal is to see which combination works better at preventing cancer recurrence.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This trial tests a new combination of two drugs (JPI-547 and bevacizumab) as maintenance therapy after platinum-based chemotherapy and a PARP inhibitor. It's for people with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA mutation or HRD deficiency.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.